share_log

Altimmune | 8-K: Current report

Altimmune | 8-K: Current report

Altimmune | 8-K：重大事件
美股sec公告 ·  06/26 07:38
Moomoo AI 已提取核心訊息
Altimmune, Inc., a clinical-stage biopharmaceutical company, has announced the unexpected passing of its Chief Financial Officer, Richard Eisenstadt, on June 24, 2024. Following this event, the company's Board of Directors appointed Andrew Shutterly as the acting Chief Financial Officer, effective immediately. Shutterly, who has been with Altimmune since October 2020, previously served as Corporate Controller since February 2023 and has a background in accounting with experience at Meso Scale Diagnostics LLC and Deloitte. Altimmune will enter into an indemnification agreement with Shutterly similar to those with other executive officers. The company has also issued a press release expressing condolences and has begun the search for a permanent CFO replacement. Altimmune specializes in developing peptide-based therapeutics and is currently working on pemvidutide for obesity and NASH treatment.
Altimmune, Inc., a clinical-stage biopharmaceutical company, has announced the unexpected passing of its Chief Financial Officer, Richard Eisenstadt, on June 24, 2024. Following this event, the company's Board of Directors appointed Andrew Shutterly as the acting Chief Financial Officer, effective immediately. Shutterly, who has been with Altimmune since October 2020, previously served as Corporate Controller since February 2023 and has a background in accounting with experience at Meso Scale Diagnostics LLC and Deloitte. Altimmune will enter into an indemnification agreement with Shutterly similar to those with other executive officers. The company has also issued a press release expressing condolences and has begun the search for a permanent CFO replacement. Altimmune specializes in developing peptide-based therapeutics and is currently working on pemvidutide for obesity and NASH treatment.
臨床生物製藥公司Altimmune宣佈其首席財務官Richard Eisenstadt於2024年6月24日意外辭世。此後，公司董事會立即任命Andrew Shutterly爲代理首席財務官。Shutterly自2020年10月起加入Altimmune，此前自2023年2月起擔任公司控制器，並擁有Meso Scale Diagnostics LLC和德勤的會計背景。Altimmune將與Shutterly簽署類似於其他高管的賠償協議。公司還發布了一份新聞稿，表達了慰問之意，並已開始物色永久首席財務官的替代人選。Altimmune專注於開發基於肽的治療藥物，目前正在研發適用於肥胖症和NASH治療的pemvidutide。
臨床生物製藥公司Altimmune宣佈其首席財務官Richard Eisenstadt於2024年6月24日意外辭世。此後，公司董事會立即任命Andrew Shutterly爲代理首席財務官。Shutterly自2020年10月起加入Altimmune，此前自2023年2月起擔任公司控制器，並擁有Meso Scale Diagnostics LLC和德勤的會計背景。Altimmune將與Shutterly簽署類似於其他高管的賠償協議。公司還發布了一份新聞稿，表達了慰問之意，並已開始物色永久首席財務官的替代人選。Altimmune專注於開發基於肽的治療藥物，目前正在研發適用於肥胖症和NASH治療的pemvidutide。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息